评估肉芽肿性多血管炎和显微镜下多血管炎复发概率的评分
该研究汇总五项随机对照试验中427例GPA和MPA患者的长期随访数据,用竞争风险模型构建复发评分(FRS),并在209例独立队列中验证。FRS由PR3阳性、eGFR≥30 mL/min/1.73 m²和年龄≤75岁各计1分组成,验证队列中5年复发风险随FRS评分升高而增加。
要点
- FRS由PR3阳性、eGFR≥30 mL/min/1.73 m²和年龄≤75岁各计1分组成,总分0至3分。
- 验证队列209例中,5年复发风险FRS 0分为8%、1分为30%、2分为48%、3分为76%。
- FRS可在诊断时用于评估GPA或MPA患者的复发风险,其用于调整维持治疗时长的价值有待前瞻性试验评估。
核心结论
- FRS可在诊断时用于评估GPA或MPA患者的复发风险,其用于调整维持治疗时长的价值应在未来前瞻性试验中评估。
研究设计与样本
- 汇总五项连续随机对照试验中GPA和MPA患者的长期随访数据,将诊断时患者特征纳入竞争风险模型,以复发为感兴趣事件、死亡为竞争事件,进行单变量和多变量分析以识别与复发相关的变量并构建评分,随后在独立的GPA或MPA患者队列中验证。
- 纳入分析的是427例患者(203例GPA,224例MPA)诊断时收集的数据,平均±标准差随访80.6±51.3个月。
- 验证队列包含209例患者。
主要发现
- 207例(48.5%)患者经历至少1次复发。
- 复发风险与诊断时蛋白酶3(PR3)阳性相关(HR=1.81(95% CI 1.28至2.57);p<0.001)。
- 复发风险与诊断时年龄≤75岁相关(HR=1.89(95% CI 1.15至3.13);p=0.012)。
- 复发风险与诊断时估算肾小球滤过率(eGFR)≥30 mL/min/1.73 m²相关(HR=1.67(95% CI 1.18至2.33);p=0.004)。
- 验证队列209例中,5年复发风险FRS 0分为8%、FRS 1分为30%、FRS 2分为48%、FRS 3分为76%。
关键数值与推荐
- 法国血管炎研究组复发评分(FRS)为0至3分模型:PR3-抗中性粒细胞胞质抗体阳性计1分、eGFR≥30 mL/min/1.73 m²计1分、年龄≤75岁计1分。
临床怎么用
- FRS可在诊断时用于评估GPA或MPA患者的复发风险。
- FRS用于调整维持治疗时长的价值应在未来前瞻性试验中评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop a score assessing the probability of relapse in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). METHODS: Long-term follow-up data from GPA and MPA patients included in five consecutive randomised controlled trials were pooled. Patient characteristics at diagnosis were entered into a competing-risks model, with relapse as the event of interest and death the competing event. Univariate and multivariate analyses were computed to identify variables associated with relapse and build a score, which was then validated in an independent cohort of GPA or MPA patients. RESULTS: Data collected from 427 patients (203 GPA, 224 MPA) at diagnosis were included. Mean±SD follow-up was 80.6±51.3 months; 207 (48.5%) patients experienced ≥1 relapse. Relapse risk was associated with proteinase 3 (PR3) positivity (HR=1.81 (95% CI 1.28 to 2.57); p<0.001), age ≤75 years (HR=1.89 (95% CI 1.15 to 3.13); p=0.012) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m² (HR=1.67 (95% CI 1.18 to 2.33); p=0.004) at diagnosis. A score, the French Vasculitis Study Group Relapse Score (FRS), from 0 to 3 points was modelised: 1 point each for PR3-antineutrophil cytoplasmic antibody positivity, eGFR ≥30 mL/min/1.73 m² and age ≤75 years. In the validation cohort of 209 patients, the 5-year relapse risk was 8% for a FRS of 0, 30% for 1, 48% for 2 and 76% for 3. CONCLUSION: The FRS can be used at diagnosis to assess the relapse risk in patients with GPA or MPA. Its value for tailoring the duration of maintenance therapy should be evaluated in future prospective trials.
引用
- Samson M, Devilliers H, Thietart S, et al. Score to assess the probability of relapse in granulomatosis with polyangiitis and microscopic polyangiitis. RMD Open. 2023. PMID: 36972927. doi:10.1136/rmdopen-2022-002953
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。